American Herbal Products Association (AHPA) > About Us > Committees > Government Relations Committee

Government Relations Committee

Chair: Staci Eisner (Cortex Scientific)
Staff Contact: Michael McGuffin

Committee Purpose:

  • To monitor legislative and regulatory issues and agencies for the purpose of developing industry positions that conform to AHPA's mission.

AHPA Members, if you would like to join this committee, please email the staff contact.

Committee Resources

Committee Meeting Minutes

May 27, 2021 Meeting Minutes

Meeting of the Government Relations Committee

November 16 + December 14, 2021 Meeting Minutes

Meeting of the Government Relations Committee

August 4, 2021 Meeting Minutes

Meeting of the Government Relations Committee

June 3, 2021 Meeting Minutes

Meeting of the Government Relations Committee

April 27, 2021 Meeting Minutes

Meeting of the Government Relations Committee

RSS
12

Committee-Related News

FDA releases NDI enforcement discretion draft guidance

May 2022: Final guidance will provide opening for NDI notification “catch-up submissions”

FDA has released a draft guidance outlining a proposed policy of enforcement discretion regarding the late submission of new dietary ingredient (NDI) notifications. Upon the release of a finalized guidance, companies will be able to electronically submit late NDIs to FDA for a set period (currently 180 days in the draft guidance) without penalty.

Initial AHPA time study results suggest nearly $20 million initial compliance price tag for Durbin/Braun product listing bill

May 2022: Early data do not include initial training costs or follow-on costs for label revisions or new products

The American Herbal Products Association (AHPA) has estimated the dietary supplement industry will need to spend nearly 20 million dollars for initial compliance with the Dietary Supplement Listing Act, a bill introduced by Senators Richard Durbin (D-IL) and Mike Braun (R-IN) that would establish a requirement for mandatory product listing (MPL) for all dietary supplements marketed in the United States.

Senate HELP Committee publishes draft bill including MPL, new cosmetics regulations

May 2022: AHPA Update

The United States Senate Committee on Health, Education, Labor and Pensions (HELP) has released a “discussion draft” of the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, a piece of must-pass legislation that reauthorizes drug and medical device user fee programs.

AHPA opposes Dietary Supplement Listing Act

April 2022: Statement of AHPA President Michael McGuffin

The American Herbal Products Association (AHPA) is announcing opposition to the Dietary Supplement Listing Act introduced by Senators Richard Durbin (D-IL) and Mike Braun (R-IN) that would establish a requirement for mandatory product listing (MPL) for all dietary supplements marketed in the United States.

AHPA’s Michael McGuffin discusses MPL, NAC, and modernizing dietary supplement regulations on “Short Legal Briefs”

April 2022

In the most recent episode of “Short Legal Briefs,” AHPA President Michael McGuffin joined host Josh Long and fellow industry trade association leaders to discuss mandatory product listing (MPL), N-acetyl-L-cysteine (NAC), and modernizing dietary supplement regulations.

AHPA asks US Trade Representative for reconsideration of herbal ingredient tariff

April 2022: Court of International Trade has ordered US Trade Representative to reconsider China tariff lists

The American Herbal Products Association (AHPA) has contacted the U.S. Trade Representative requesting the removal of punitive tariffs from a range of products relevant to the herbal products industry.

FDA decommissions “Poisonous Plant Database”

February 2022: AHPA had requested website corrections since 2017

The U.S. Food and Drug Administration (FDA) has decommissioned an inaccurately titled repository of references following several years of requests by the American Herbal Products Association (AHPA) for the agency to address confusion created by this FDA product.

Lawsuit aimed at self-affirmed GRAS dismissed by Federal Court

October 2021: AHPA Update

The United States District Court for the Southern District of New York last week entered summary judgment in favor of the United States Food and Drug Administration (FDA) in a suit filed in 2017 that sought to overturn FDA’s allowance for the GRAS self-affirmation process commonly used to document the safety of new food ingredients.

Opposition to mandatory product listing outweighs support in AHPA member survey

October 2021: AHPA Update

The Food and Drug Administration (FDA) has called on the U.S. Congress to pass legislation that would require mandatory product listing (MPL) for all dietary supplements in the United States.

AHPA submits comments to the “Cannabis Administration and Opportunity Act” Discussion Draft

September 2021: AHPA Update

On September 1, 2021, AHPA submitted comments to the Senate sponsoring offices for the “Cannabis Administration and Opportunity Act” (CAOA) Discussion Draft.

RSS
123